Inozyme Pharma, Inc.
inozyme.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q1 FY2025 10-Q, filed May 14, 2025. Its latest SEC filing is a SCHEDULE 13D/A from Aug 27, 2025.
10-Q for Q1 FY2025, filed May 14, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops an investigational enzyme therapy for rare diseases affecting bones and blood vessels, including inherited mineralization disorders and calciphylaxis.
10-K for FY2024, filed Mar 10, 2025
How Did They Make Money?
No revenue was reported.
10-K for FY2024, filed Mar 10, 2025
How Were They Changing?
- Net income
-
Sources
10-Q for Q1 FY2025, filed May 14, 2025
−$28MView ↗
- ▲ +20% (Loss)
- vs −$23.3M in Q1 FY2024
-
Jul 1, 2025
BioMarin completed its acquisition of Inozyme
Inozyme became a wholly owned subsidiary, and asked Nasdaq to delist its shares.
Sources
8-K, filed Jul 1, 2025
Following consummation of the Offer, the conditions to the merger set forth in the Merger Agreement were satisfied, and on July 1, 2025…View ↗
Narrower development focus
The older report described clinical plans for inherited deficiencies; the latest prioritizes preparing a marketing application for its lead disease and postpones future trials for an additional deficiency.
10-K for FY2021, filed Mar 15, 2022 10-K for FY2024, filed Mar 10, 2025
Who Did They Compete With?
Competes with Daiichi Sankyo
10-K for FY2024, filed Mar 10, 2025There are currently no approved therapies for the treatment of ENPP1 Deficiency. Currently available treatments are only seeking to…View ↗
Loading...
